China’s Epigenic Therapeutics secured $60 million in Series B financing to propel clinical development of its lead gene therapy candidates EPI-003, targeting chronic hepatitis B, and EPI-001 for hypercholesterolemia. Employing novel CRISPR epigenetic editing technology, Epigenic aims to offer transformative therapies for persistent viral infections and metabolic diseases. The funding round highlights robust investor confidence in precision epigenetic modulation as a therapeutic avenue and sets the stage for upcoming clinical trials.